Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.46 USD
Change Today +0.265 / 0.42%
Volume 829.4K
STJ On Other Exchanges
As of 12:13 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

electrode. The FlexAbility ablation catheter (FDA approval in January 2015) is designed using physician input from concept to completion and has the same irrigated catheter tip as the Cool Flex ablation catheter. This tip is integrated onto a next generation shaft and handle platform to provide performance and maneuverability. The company, through its acquisition of Endosense, expands its presence in the ablation catheter segment. The TactiCath Quartz ablation catheter with its force-sensing technology provides physicians a real-time measure of contact force being applied between the catheter tip and the endocardial tissue surface during cardiac electrophysiological mapping and catheter ablation procedures (FDA approval in October 2014 and European CE Mark approval in 2012). The company has the potential to integrate the force-sensing technology to offer a MediGuide-enabled force-sensing ablation catheter and incorporate force-sensing data into the company’s Ensite Velocity Mapping System. Interventional EP procedures, including catheter ablations and CRT procedures, expose operators, staff and patients to the risks of fluoroscopy. The company’s MediGuide technology is a platform to facilitate the reduction of fluoroscopy exposure while also increasing procedural efficiencies. The MediGuide technology consists of a hardware system, which is integrated with the EP lab fluoroscopy system. Other products offered by the company would also integrate with the MediGuide technology, including MediGuide sensor-enabled diagnostic and irrigated ablation catheters, the EnSite Velocity system and certain CRT delivery tools. The company continues to expand its MediGuide technology platform as additional integrated products are developed and approved. Early clinical work has demonstrated that the MediGuide technology could reduce radiation exposure during EP lab procedures for physicians, patients and staff. The company’s EP-WorkMate recording system is used to monitor electrical activity of the heart through intracardiac catheters and features the company’s new ClearWave technology for high-fidelity signals and an integrated stimulator, its EP 4 Cardiac Stimulator. The company also offers the VantageView System, which is a high resolution 56 inches monitor that allows the display of eight video inputs. The VantageView System would accommodate various video input signals and then display images that could be resized and relocated with high resolution. The VantageView System is programmed with a touch screen and could be customized to meet the needs of the physician and/or procedure. The company also offers its Confirm implantable cardiac monitor device (FDA approval and European CE Mark approval in 2008). This small implantable device is designed to help physicians monitor abnormal cardiac rhythms. Vascular Products The company’s vascular products include active vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, a HF monitoring device (CardioMEMS (CardioMEMS, Inc.)), renal denervation technology, and vascular plugs. The company’s vascular closure devices are used to close femoral and radial artery puncture sites following percutaneous coronary interventions (PCIs), diagnostic procedures, and certain peripheral procedures. Active or passive (manual) compression is utilized to assist in closing artery puncture sites. The company’s active closure devices include its Angio-Seal product offering. The new version is the Angio-Seal Evolution, which features automated collagen compaction, making it easier for the clinician to deploy the device and obtain arterial hemostasis (cessation of bleeding). Prior versions of Angio-Seal, Angio-Seal VIP and Angio-Seal STS Plus continue to generate revenue in the company’s active closure product offering. The company’s compression assist device offerings include both the RadiStop and FemoStop compression assist devices to close puncture sites of the radial and femoral arteries, respectively. Compression assist devices are used to maintain pressure on


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $63.46 USD +0.265

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.77 USD -0.025
CR Bard Inc $186.82 USD -0.205
Olympus Corp ¥3,840 JPY -15.00
Smith & Nephew PLC 1,126 GBp -2.00
Zimmer Biomet Holdings Inc $96.44 USD +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 17.4x
Price/Sales 3.2x
Price/Book 4.6x
Price/Cash Flow 15.6x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at